This inventor holds 1 USPTO granted patent and 8 published patent applications. Top assignee: University of California. Active years: 2000.
Company Filing History:
Years Active: 2000
Title: The Innovations of Peter W Vanderklish
Introduction
Peter W Vanderklish is an accomplished inventor based in Laguna Beach, California. He has made significant contributions to the field of neuroscience, particularly in the modulation of AMPA receptors to enhance brain neurotrophic factors. His work aims to address neurodegenerative pathologies while preserving cognitive functions such as memory and learning.
Latest Patents
Peter W Vanderklish holds a patent titled "Positive AMPA receptor modulation to enhance brain neurotrophic factor." This patent focuses on methods for increasing the levels of neurotrophic factors and their receptors in the brains of mammals suffering from neurodegeneration. The innovative approach involves administering an effective amount of an allosteric upmodulator of AMPA receptors, which can potentially lead to breakthroughs in treating neurodegenerative diseases without significant cognitive decline. He has 1 patent to his name.
Career Highlights
Peter is affiliated with the University of California, where he conducts research and develops his innovative ideas. His academic background and research experience have positioned him as a key figure in the field of neurobiology. His work not only contributes to scientific knowledge but also has the potential to impact therapeutic strategies for various neurological conditions.
Collaborations
Peter has collaborated with notable colleagues, including Julie C Lauterborn and Christine M Gall. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in neuroscience.
Conclusion
Peter W Vanderklish is a pioneering inventor whose work in AMPA receptor modulation represents a significant advancement in neuroscience. His contributions have the potential to improve the lives of individuals affected by neurodegenerative diseases.
